Senate Files

Bills

H.R. 1492 119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Latest action, Feb 21, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

68 cosponsors

Sponsored by Rep. Murphy, Gregory F. [R-NC-3] (Republican). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
4 D · 64 R

Referred to: House: Energy and Commerce Committee; House: Ways and Means Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

59 clientsQ1 2025Q3 2026

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

ACADIA PHARMACEUTICALS
7 reports
AMGEN INC
7 reports
AMGEN USA INC.
MARSHALL & POPP, LLC
7 reports
BAYER CORPORATION (CONSOLIDATED REPORT)
7 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
7 reports
BOEHRINGER INGELHEIM USA CORPORATION
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
7 reports
EMD SERONO INC
7 reports
GENENTECH, INC.
MARSHALL & POPP, LLC
7 reports
GILEAD SCIENCES, INC.
THE MCMANUS GROUP
7 reports
GSK (FKA GLAXOSMITHKLINE INC.)
7 reports
HEALTHCARE INSTITUTE OF NEW JERSEY
7 reports
JOHNSON & JOHNSON SERVICES INC
7 reports
LUNDBECK LLC
7 reports
NEUROCRINE BIOSCIENCES, INC
7 reports
NOVARTIS
7 reports
All 25 of 71 clients
ClientLobbying firmReportsReports totalingFromToSenate
ACADIA PHARMACEUTICALS7$4.0MQ1 2025Q3 2026yes
AMGEN INC7$21.5MQ1 2025Q3 2026yes
AMGEN USA INC.MARSHALL & POPP, LLC7$0Q1 2025Q3 2026yes
BAYER CORPORATION (CONSOLIDATED REPORT)7$14.8MQ1 2025Q3 2026yes
BIOTECHNOLOGY INNOVATION ORGANIZATION7$12.1MQ1 2025Q3 2026yes
BOEHRINGER INGELHEIM USA CORPORATIONBOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC7$6.6MQ1 2025Q3 2026yes
EMD SERONO INC7$5.4MQ1 2025Q3 2026yes
GENENTECH, INC.MARSHALL & POPP, LLC7$0Q1 2025Q3 2026yes
GILEAD SCIENCES, INC.THE MCMANUS GROUP7$0Q1 2025Q3 2026yes
GSK (FKA GLAXOSMITHKLINE INC.)7$8.9MQ1 2025Q3 2026yes
HEALTHCARE INSTITUTE OF NEW JERSEY7$333KQ1 2025Q3 2026yes
JOHNSON & JOHNSON SERVICES INC7$15.5MQ1 2025Q3 2026yes
LUNDBECK LLC7$1.1MQ1 2025Q3 2026yes
NEUROCRINE BIOSCIENCES, INC7$6.4MQ1 2025Q3 2026yes
NOVARTIS7$14.0MQ1 2025Q3 2026yes
NOVO NORDISK, INC.THE NICKLES GROUP, LLC7$0Q1 2025Q3 2026yes
PFIZER, INC.MARSHALL & POPP, LLC7$0Q1 2025Q3 2026yes
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATIONE3 STRATEGIC CONSULTING GROUP7$380KQ1 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAAEGIS LLC7$0Q1 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA7$64.5MQ1 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICATHE MCMANUS GROUP7$0Q1 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAMARSHALL & POPP, LLC7$0Q1 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)ADVANCED POLICY CONSULTING, LLC7$280KQ1 2025Q3 2026yes
PHRMAWILLIAMS AND JENSEN, PLLC7$350KQ1 2025Q3 2026yes
PTC THERAPEUTICS, INC.7$1.3MQ1 2025Q3 2026yes